Stryker Corp (SYK)

Stryker Launches Pangea Plating System and Completes First Case in EuropeMay 26, 2026 2:10 AM
Business Wire Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525326817/en/Stryker's Pangea Plating System brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures. “Pangea was developed with a clear goal in mind: supporting anatomical fit while maintaining simplicity in the operating room,” said Prof. Trompeter. “The system brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures.” The devices are non-active implants intended to provide temporary stabilization for bones or bone fragments. The system includes plates and complementary instrumentation intended to support plate fit and provide surgeons with options for fracture fixation across the upper and lower extremities. “Having used the system in the U.S., I’ve seen how it supports consistent workflows while offering flexibility in fracture fixation,” said Arvind von Keudell, MD, PhD, MPH, fellowship-trained, board-certified orthopaedic surgeon and associate professor at Harvard Medical School. “It’s designed in a way that helps surgeons adapt to different fracture patterns without adding unnecessary complexity in the operating room.” Developed in collaboration with 26 orthopaedic surgeons from around the world, the Pangea portfolio incorporates global anatomical data to support plate fit across diverse patient populations. The platform also provides variable-angle plating designed to offer flexibility in screw placement. “We are pleased to introduce the Pangea Plating System to surgeons across Europe,” said Dragana Bunjevac, vice president and general manager of Stryker’s Trauma & Extremities division in EMEA. “Pangea reflects our focus on developing solutions that enhance surgical workflow and address the evolving needs of trauma care.” The European launch expands access to Stryker’s trauma portfolio and reflects the company’s continued collaboration with orthopaedic surgeons worldwide to develop solutions that support fracture fixation. For more information about the Pangea Plating System, please visit our website. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com. This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery. The information presented is intended to demonstrate a Stryker product. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area. The instructions for use, operative techniques, cleaning instructions, patient information leaflets and other associated labeling may be requested online at ifu.stryker.com or stryker.com. If saving the instructions for use, operative techniques, cleaning instructions from the above mentioned websites, please make sure you always have the most up to date version prior to use. Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Pangea, Stryker. All other trademarks are trademarks of their respective owners or holders. Content ID: TR-PANG-PRESS-3206883 View source version on businesswire.com: https://www.businesswire.com/news/home/20260525326817/en/ Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
jenny.braga@stryker.com Original: Stryker Launches Pangea Plating System and Completes First Case in Europe

BioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech EcosystemMay 19, 2026 5:30 AM
Business Wire Three companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio. All three companies have close ties to Michigan. BioStar Capital, with offices in Michigan and Ohio, was founded by Dr. Louis Cannon, a physician who first encountered the idea for hydraulic lithotripsy while serving on the University of Michigan’s Coulter Committee. Robert Chisena, Ph.D, co-founded AVS while completing his doctorate at the university, building prototypes in an Ann Arbor garage. He developed the technology in partnership with Hitinder S. Gurm, an interventional cardiologist and interim Chief Medical Officer of the U of M Health System. Stryker is headquartered in Portage, in southwest Michigan. About 1 in 20 U.S. adults, aged 20 and older, have calcified arteries, the treatment of which costs approximately $100 billion in aggregate annually. AVS’s Pulse System is a much-needed alternative to the current interventions that use electric wired balloons and lasers. AVS’s technology, which delivers CO2-generated pressure waves through a balloon catheter, optimizes arterial diameter while potentially minimizing damage and increasing catheter deliverability, treatment speed, and therapeutic efficacy. BioStar Capital served as an early strategic growth partner of AVS, licensing the IP, providing initial startup capital, and guiding the startup through several phases of development and approvals, including clinical studies and first-in-human trial design. “We are doctors first and investors second, which means we look for emerging technologies that solve the needs of physicians and patients, then work to make the product better and scalable,” said Cannon, BioStar’s Senior Managing Director. “The data shows that this device is uniquely safe and effective.” “Its potential for tremendous impact on patients’ lives has only increased with the benefit of Stryker’s resources and reach,” Cannon added. This acquisition is the latest in a long history of successful exits for BioStar Capital. Among others, the firm previously invested in Corindus Vascular Robotics (NYSE: CVRS), a leader in robotic-assisted vascular interventions that was acquired by Siemens Healthineers for $1.1 billion; V-Wave, a company addressing heart failure that was acquired by Johnson & Johnson for up to $1.7 billion; and CathWorks, developer of an AI-powered imaging platform for coronary artery disease that was acquired by Medtronic in a deal valuing up to $585 million. About BioStar Capital BioStar Capital invests in and nurtures transformative medical technologies. The team consists of renowned healthcare clinicians, medical thought leaders, and financial professionals who bring unique insight to every investment opportunity. By leveraging a rare combination of domain expertise, industry connections, and access to medical facilities and innovators, BioStar Capital has consistently produced life-changing outcomes for patients and rewarding returns for investors. View source version on businesswire.com: https://www.businesswire.com/news/home/20260519752884/en/ Media Contacts
Chelsea Saraf
Marketing Consultant
Marketing & Communications
(231) 437-7622
csaraf@biostarcapital.com Original: BioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech Ecosystem

Stryker shares climb after company says cybersecurity incident containedMarch 23, 2026 10:57 AM
IH Market News
Shares of Stryker (NYSE:SYK) gained 2.82% to $345.14 in premarket trading on Monday after the medical device manufacturer said it had contained a recent cybersecurity incident.The company said its investigation has found no indication that the event affected systems belonging to customers, suppliers, vendors or other partners.Stryker said the breach involved a malicious file that was used to conceal activity but was unable to propagate either within the company’s internal systems or externally. The investigation was carried out with support from Palo Alto Networks’ (NASDAQ:PANW) Unit 42 cybersecurity team.According to the company, the incident impacted parts of its corporate network, including elements of its Microsoft (NASDAQ:MSFT) environment.The investigation remains ongoing, and Stryker said it has not yet determined whether the incident could have any material impact on its business operations or financial results.Stryker stock price

Original: Stryker shares climb after company says cybersecurity incident contained

Stryker says cyberattack contained, prioritizes restoring customer-facing systemsMarch 17, 2026 9:42 AM
IH Market News
Medical technology company Stryker (NYSE:SYK) said Tuesday it has contained a cyberattack that disrupted parts of its operations and is now focused on restoring systems tied to customer support, order processing and shipping.The company said the incident began on March 11 and temporarily affected several operational functions, including order management, manufacturing and product shipments. A hacking group known as Handala, believed to have links to Iran, claimed responsibility for the attack that same day, saying it was carried out in retaliation for a strike on a girls’ school in Minab in southern Iran.Stryker said the breach impacted devices such as cellphones, laptops and other remote systems running Microsoft Windows that were able to connect to its internal networks.The company added that patient-related services and connected medical devices were not affected by the attack. However, it did not disclose any details regarding the potential financial consequences of the disruption.Stryker, which employs around 56,000 people and operates across 61 countries, said it is working with relevant authorities and external cybersecurity specialists as part of its ongoing investigation into the incident.Stryker stock price

Original: Stryker says cyberattack contained, prioritizes restoring customer-facing systems

MedTech Giant Stryker Crippled by Iran-Linked Hacker Attack

~ Stryker was targeted by the Handala group, which claims to have wiped more than 200,000 of the company’s devices.

~ by Eduard Kovacs, March 11, 2026

Medical technology giant Stryker has been targeted by a highly disruptive cyberattack carried out by an Iran-linked hacker group.

Stryker is a Fortune 500 company that specializes in the manufacturing of surgical equipment, orthopedic implants, and neurotechnology. Headquartered in Michigan, the company employs approximately 56,000 people and reported over $25 billion in revenue for 2025. Its critical role in the healthcare supply chain makes it an essential partner for hospitals worldwide.

The Iran-linked hacker group named Handala has taken credit for the attack, claiming to have struck an “unprecedented blow” to the company.

The hackers claim to have wiped more than 200,000 servers, mobile devices, and other systems, forcing Stryker to shut down offices in 79 countries. They also allegedly stole 50TB of data from the company’s systems.

(read more from the following IH message link:)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177386634






•

Stryker shares slide after report of Iran-linked cyberattackMarch 11, 2026 11:58 AM
IH Market News
Stryker Corporation (NYSE:SYK) fell about 3.4% on Wednesday after a report by The Wall Street Journal said the medical device maker had been targeted in a cyberattack tied to an Iran-linked hacking group.According to the report, the company is experiencing widespread system outages globally. Employees and contractors said the logo of a hacking group connected to Iran appeared on company login screens, with the disruption beginning shortly after midnight on the U.S. East Coast.Sources cited by the Journal said remote devices running Microsoft Windows—including smartphones, laptops and other hardware configured to access Stryker’s internal systems—had been wiped.The company instructed employees not to power on corporate-issued devices and to disconnect immediately from all networks, according to an internal email reviewed by WSJ Pro Cybersecurity. The message also advised staff to avoid clicking suspicious links and to remove mobile device management applications and work profiles from their phones.Stryker is among the largest medical technology companies globally, producing equipment and devices used in hospitals and surgical environments, particularly in orthopedics and neurosurgery.Stryker stock price

Original: Stryker shares slide after report of Iran-linked cyberattack

Stryker launches SmartHospital PlatformMarch 9, 2026 9:07 AM
PR Newswire (US)

New platform connects devices, data and care teams across the patient journey to streamline operations and enhance outcomes for patients and staffPORTAGE, Mich., March 9, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced its new SmartHospital Platform, a digital foundation designed to connect devices, data and care teams across the hospital into one intelligent, adaptive ecosystem. The launch comes ahead of the 2026 HIMSS Global Conference & Exhibition and marks a significant expansion of Stryker's digital offerings.







The SmartHospital Platform is being led by Stryker's new Smart Care business, established to advance the company's ongoing commitment to supporting their customers' digital transformations. Built to help address today's healthcare challenges, including system fragmentation, staff overload and high patient volumes, the SmartHospital Platform scales to support the unique needs of hospitals and health systems, surfacing relevant insights to inform clinical decisions and enhance workflow efficiency."We are dedicated to partnering with our customers on their digital journeys to help elevate care delivery," said Scott Sagehorn, VP/GM of Smart Care at Stryker. "The SmartHospital Platform is designed to evolve alongside health systems so teams can work more efficiently and stay focused on patient-centered care."Key capabilities of the SmartHospital Platform include:Connected infrastructure: The platform connects devices and data to support clinical and operational workflows across transport, treatment and recovery, helping teams better coordinate patient care.Clinical communication: Voice-activated, hands-free communication devices such as Stryker's Sync Badge give teams critical information and prioritized alarms to support timely, coordinated care delivery across the hospital.Workflow engine: Engage, the intelligent middleware engine behind the SmartHospital Platform, helps reduce communication silos by filtering and prioritizing alarms and notifications so staff can stay informed across busy care settings.Virtual care: Virtual nursing and virtual monitoring workflows help support bedside staff by streamlining administrative tasks and empowering them to stay focused on the patient experience.Ambient intelligence: Ambient sensors, computer vision, AI and contextual data help the care environment become more aware, adaptive and responsive."Launching the SmartHospital Platform is an important step forward in supporting our customers as they transform care delivery," said Jessica Mathieson, president of Medical at Stryker. "We remain focused on solving problems, helping nurses and staff spend less time navigating complexity and more time with patients."About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.To learn more about the SmartHospital Platform, visit stryker.com/smarthospitalplatform Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
jenny.braga@stryker.com  










View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-launches-smarthospital-platform-302707076.htmlSOURCE Stryker

Original: Stryker launches SmartHospital Platform

Stryker launches Synchfix™ EVT, expanding options for flexible syndesmotic fixationFebruary 24, 2026 8:41 AM
PR Newswire (US)

Elevating care with Stryker's next generation device, Synchfix EVT, which will be featured at the 2026 American College of Foot and Ankle Surgeons (ACFAS) Annual MeetingPORTAGE, Mich., Feb. 24, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of Synchfix™ EVT, its next-generation flexible syndesmotic fixation device designed to simplify surgical deployment while supporting ankle stabilization in patients with syndesmotic disruptions.







Commonly associated with sports trauma and ankle fractures, ankle syndesmotic injuries can significantly affect patient mobility and recovery. Synchfix EVT builds on the legacy Synchfix platform, incorporating design enhancements that reduce procedural complexity compared to the predicate device."Stryker is dedicated to helping foot and ankle surgeons treat their patients more efficiently while enhancing patient care and the overall healthcare experience," said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. "Synchfix EVT reflects our commitment to delivering next-generation solutions in soft tissue by designing technologies that help surgeons work more efficiently while keeping patient care and safety at the center."Synchfix EVT features an all-in-one system that integrates suture tensioning handles within the implant instrumentation, along with a handle design for one-handed surgical implant deployment. The device is engineered to provide a seamless user experience with an ergonomic handle and a low-profile titanium medial implant.Synchfix™ EVT is intended for soft tissue and bone fixation for ankle syndesmosis disruptions with or without ankle fractures and as an adjunct in connection with hardware for ankle fractures such as Weber B, Weber C and Maisonneuve in adult and adolescent patient populations. Notably, it is the first ankle syndesmotic flexible fixation device on the market indicated for use in adolescents, expanding treatment options for younger patients. The system has also been recognized with the prestigious Red Dot Design Award, honoring its innovative, all-in-one implant and instrumentation designed to simplify syndesmotic fixation and enhance surgical efficiency compared to the previous generation of the device."At Stryker, we're continually energized by our customers' commitment to their patients," said Jacobs. "Synchfix EVT demonstrates how listening to their needs helps shape meaningful design and procedural advancements."Stryker is showcasing Synchfix EVT at the ACFAS meeting. The event will feature engaging demonstrations that will highlight how this sterile, single-use, knotless, and flexible, suture-button system is designed to stabilize syndesmotic ankle injuries.About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.Media contact
Frank Mastrangelo
Director, Communications
Stryker Trauma & Extremities
frank.mastrangelo@stryker.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-launches-synchfix-evt-expanding-options-for-flexible-syndesmotic-fixation-302694946.htmlSOURCE Stryker

Original: Stryker launches Synchfix™ EVT, expanding options for flexible syndesmotic fixation

Stryker launches T2 Alpha Humerus Nailing System, supporting surgical workflow and care for complex fracturesFebruary 11, 2026 9:03 AM
PR Newswire (US)

PORTAGE, Mich., Feb. 11, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of the T2 Alpha Humerus Nailing System, the latest addition to its T2 Alpha portfolio. The system offers surgeons a streamlined approach to humeral fracture fixation while providing hospital teams with a unified platform that enables consistent, high-quality care. 







Designed using Stryker's SOMA (Stryker Orthopaedic Modeling and Analytics) technology, the T2 Alpha Humerus Nailing System helps manage complex humerus fractures, including non-unions, malunions, malalignments and pathological fractures. Its advanced nail design is intended to align with the patient's anatomy, 1 enhance fixation stability, and provide flexibility.The T2 Alpha Humerus Nailing System is built to simplify procedures and expand treatment options through intuitive instrumentation and guided targeting, supporting ease of use in the operating room. By integrating with Stryker's existing nailing platform, it promotes familiarity and consistent workflows across procedures, helping to streamline training, reduce tray requirements and support hospital process efficiencies.Key features of the T2 Alpha Humerus System include:SOMA-informed nail design based on CT data across diverse populations to facilitate anatomical fit and alignment1Active intraoperative compression of up to 6mm to provide controlled fracture reduction compared to traditional methods6Multiplanar screw fixation with advanced locking options designed to capture dense bone2 and enhance stability4,5Guided targeting instrumentation to promote reproducibility and potentially reduce radiation exposure3"With the T2 Alpha Humerus Nailing System, we are giving surgeons greater flexibility to treat complex humerus fractures with confidence," said Eric Tamweber, vice president and general manager of Stryker's Trauma business. "This addition to our T2 Alpha portfolio builds on decades of surgeon collaboration and innovation, delivering solutions designed to support consistent results while driving efficiency in the operating room."For more information, visit www.stryker.com/us/en/trauma-and-extremities/products/T2-Alpha-Humeral-Nail.html.About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.Media contact
Frank Mastrangelo
Director, Communications
Stryker Trauma & Extremities
frank.mastrangelo@stryker.comReferencesInternal Report ? D0000353370, Rev AA.Internal Report ? D0000305724, Rev AA.Konda SR, Maseda M, et al. Observational prospective unblinded case-control study to evaluate the effect of the Gamma3® distal targeting system for long nails on radiation exposure and time for distal screw placement, Injury. 2023;54(2):677-682. doi:10.1016/j.injury.2022.11.046Naidu SH, Bixler B, Capo JT, Moulton MJ, Radin A. Percutaneous pinning of proximal humerus fractures: a biomechanical study. Orthopedics. 1997;20(11):1073–6.24.Horn J, Gueorguiev B, Brianza S, Steen H, Schwieger K. Biomechanical evaluation of two-part surgical neck fractures of the humerus fixed by anangular stable locked intramedullary nail. J Orthop Trauma. 2011;25(7):406–13.T2 Alpha Humerus Nailing System Surgical Technique, TR-T2AL-SURGP-2363750, 09-2025 










View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-launches-t2-alpha-humerus-nailing-system-supporting-surgical-workflow-and-care-for-complex-fractures-302682984.htmlSOURCE Stryker

Original: Stryker launches T2 Alpha Humerus Nailing System, supporting surgical workflow and care for complex fractures

Stryker introduces Mako Handheld Robotics with the limited market release of Mako RPSFebruary 9, 2026 10:29 AM
PR Newswire (US)

PORTAGE, Mich., Feb. 9, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic system that combines Stryker's proven robotics and power tool legacies and represents Mako's expansion into a new robotics platform. Mako now includes Mako SmartRobotics™ – Stryker's multi-specialty, robotic-arm assisted platform featuring Mako 4 – and Mako Handheld Robotics with Mako RPS, which is designed to reach a new market segment.







Compatible with Stryker's Triathlon® Total Knee System, Mako RPS for Total Knee offers a solution for surgeons who are interested in the potential benefits of robotic technology and want the familiarity of a manual power tool."The Mako brand represents our relentless commitment to advancing orthopaedic patient outcomes through robotics leadership," said Mike Carlin, president of Stryker's Ortho Tech division. "With nearly 20 years of experience in orthopaedic robotics and over 2 million procedures performed across 46 countries globally, Mako has established robotics as a standard of care, and we are thrilled to add Mako RPS to the Mako family."Mako RPS for Total Knee features intraoperative planning and a robotically enabled saw with Stryker's patented active adjustment technology which responds to a surgeon's hand movements, guiding the saw to stay aligned with the surgical plan. Mako RPS integrates easily into a surgeon's workflow and provides a familiar cutting experience without the use of cutting blocks. Built to work with Stryker's multi-specialty guidance platform, Q Guidance System, Mako RPS joins a comprehensive orthopaedic technologies ecosystem designed to offer versatility to the site of care.Please visit us at booth #3339 during the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting in New Orleans to learn more about Mako SmartRobotics™ and the new Mako Handheld Robotics platform.About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
jenny.braga@stryker.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-introduces-mako-handheld-robotics-with-the-limited-market-release-of-mako-rps-302682689.htmlSOURCE Stryker

Original: Stryker introduces Mako Handheld Robotics with the limited market release of Mako RPS

Great numbers, this will go slowly up too $435 in the next month 

Expect big implant numbers

SYK 10Q due 1/28

Looking good

This will be looking for the new 52 week high soon

SYK, new 52 week high

Hasn't broken down yet. Patiently waiting for the cycle to start again. I'll bet this gets down below $300 before years end.

SYK new 52=week high

I’ll start setting my buys for $292.00, hopefully it does the classic retrace after earnings

SYK 10Q due 4/30

SYK new 52 week hi

Crazy

SYK new 52 week high

Crazy especially because there are a ton of insiders selling.
My buy back in price is at $270 now.
Might be a while before this goes back down 20%, but historically it will at some point..

SYK new 52 week high

New 52!!
Reload at 270 when the new higher low happens.

Love to see it consistently do it’s magic

SYK new 52 week high

SYK new 52 week high

Thank you SYK..
Another $52,000 profit in a quick 1 month flip.

Gonna get another 1000 shares on Monday

Bought a ton at $250

Started buying in at $257.25.
Getting some $255 shares today as well.

Gonna put in buy orders at $239, stupid markets about to roll over and this will be a safe entrance

has everyone gone to sleep on this? WTF?

Sold 272.12, waiting to reload at $245
Made $33,000 last trade.

Got filled 249 today, ready sell orders to unload at 269 again..

Made $13,000 on SYK trade.
Reloading at $250

Picked up 1000 shares@258.50, let’s roll this into some bank at $278.50!!!

Murder on the wall street this week

Crushed today.

I agree bro. Check out SECI only 306,000 shares exist and a multi billion settlement deadline is scheduled by the Judge for February 7, 2020 otherwise Trial starts in May of 2020. Literally Billions on the line here. Just a 1 Billion Dollar Judgement or Settlement would create 1 share with an approximate Value of $3,200. A perfect storm is happening here for a massive payout on technology that was stolen and intended to save FireFighters lives giving us real time GPS Tracking and VoIP Communications.

The best secret stock to keep long term

Good to know. Yes that is also what I figured. This company produces amazing medical devices that there will always be a demand for in the Emergency Medical Services sector.

Its always a great hold. Worth at least 220 right now. Only down because some didnt like the acquisition last week.

SYK going higher from here longs ? I have December 210 calls. Anyone have ideas on how SYK should do on this upcoming earnings ?

Sold a trading position at $210.50, will buy back at $192.50
That’s the plan, as I bought the shares at $175, 3 months ago.

Former MAKO CEO JOINS TITAN MEDICAL - TICKER TMDI

https://apple.news/AgYXFxFsEROmMHtrBEJGGFQ

MAKO GOT BOUGHT BY STRYKER MAYBE TMDI NEXT

Boom another all time high!